Center-Authored Papers

Filters: Author is Sobieszczyk, Magdalena E  [Clear All Filters]
2011
Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N et al..  2011.  Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects.. The Journal of infectious diseases. 204(10):1541-1549. Abstract
Sobieszczyk ME, Lingappa JR, McElrath MJ.  2011.  Host genetic polymorphisms associated with innate immune factors and HIV-1.. Current opinion in HIV and AIDS. 6(5):427-34. Abstract
2012
Etter P, Landovitz R, Sibeko S, Sobieszczyk ME, Riddler SA, Karg C, Tsibris A, Schouten J.  2012.  Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.. AIDS (London, England). Abstract
2013
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.  2013.  In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses. Abstract
Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B et al..  2013.  Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.. Journal of acquired immune deficiency syndromes (1999). Abstract
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD et al..  2013.  Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine. Abstract
2015
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC et al..  2015.  Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.. PloS one. 10(9):e0136626. Abstract
Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME.  2015.  Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.. Clinical trials (London, England). Abstract
Williams WB, Liao H-X, Moody AM, Kepler TB, Alam MS, Gao F, Wiehe K, Trama AM, Jones K, Zhang R et al..  2015.  Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.. Science (New York, N.Y.). Abstract
Fuchs JD, Bart P-A, Frahm N, Morgan C, Gilbert PB, Kochar N, De Rosa SC, Tomaras GD, Wagner TM, Baden LR et al..  2015.  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5) Abstract